Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pentetate→

Pentetate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
80529-93-7
Molecular formula
C14H20N3O10-3
Molecular weight
390.32 g/mol
Drug class
Diethylenetriaminepentaacetate (DTPA) chelating agentradiodecorporation ligand in specific salt forms
Mechanism of action
Forms stable coordination complexes with selected polyvalent metal and transuranic ions, increasing their urinary elimination. Calcium-DTPA and zinc-DTPA differ in use and handling; the specific salt form is essential to clinical interpretation.
Indications / reported uses
  • Pentetate calcium trisodium and pentetate zinc trisodium products are used under specific product labels for internal contamination with plutonium, americium or curium. The unspecific name pentetate alone does not define a clinical product or salt form.

Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021749s008lbl.pdf · https://www.fda.gov/drugs/bioterrorism-and-drug-preparedness/questions-and-answers-calcium-dtpa-and-zinc-dtpa-updated · https://www.fda.gov/emergency-preparedness-and-response/medical-countermeasure-mcm-issues/radiological-and-nuclear-emergency-preparedness · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pentetate Environmental Risk Assessment (ERA) (the Pentetate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.